Pharmaceutical Companies, Research, Structure Based Drug Design (SBDD) and Treatment

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

Pharmaceutical Companies

Research

Structure Based Drug Design (SBDD)

Treatment

Sosei Heptares’ COVID-19 Program Identifies Potent Broad Spectrum Anti-Viral Small Molecules for Further Development

The Pharma Data

NOVEMBER 19, 2020

Structure-based design approach has identified potent compounds for further development as oral treatments for SARS-CoV-2 infection and related human coronaviruses. Program focused on inhibitors of SARS-CoV-2 main protease, a highly conserved protein essential for viral replication. References.

Small Molecule

Small Molecule Structure Based Drug Design (SBDD) Molecular Biology International

Sosei Heptares and Captor Therapeutics Enter Strategic Technology Collaboration Focused on Targeted GPCR Degradation as Novel Approach for Drug Design

The Pharma Data

DECEMBER 21, 2020

A further aim of the collaboration is to generate high resolution structural information around the GPCR-E3 ligase complex to enhance drug discovery efforts as well as provide proof of concept for targeted degradation discovery approaches with other GPCRs and other target classes. ” About Sosei Heptares.

Targeted Protein Degradation

Targeted Protein Degradation Small Molecule Structure Based Drug Design (SBDD) International

Drug Discovery Digest

Sosei Heptares’ COVID-19 Program Identifies Potent Broad Spectrum Anti-Viral Small Molecules for Further Development

Sosei Heptares and Captor Therapeutics Enter Strategic Technology Collaboration Focused on Targeted GPCR Degradation as Novel Approach for Drug Design

Stay Connected